- Zacks
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
- Investor's Business Daily
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record
Avidity unveiled "impressive" results from a study of its treatment for a rare form of muscular dystrophy. The top biotech stock soared.
- Motley Fool
2 Potentially High-Reward Growth Stocks to Buy Right Now
These two biotechnology stocks could be gearing up for a run.
